These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Levamisole in rheumatoid arthritis. Final report on a randomised double-blind study comparing a single weekly dose of levamisole with placebo. Multicentre Study Group.
    Journal: Ann Rheum Dis; 1982 Apr; 41(2):159-63. PubMed ID: 7041831.
    Abstract:
    The therapeutic effect of a single weekly dose of levamisole in patients with rheumatoid arthritis was compared with placebo for 6 months in a 13-centre double-blind controlled study. 281 patients with classic or definite rheumatoid arthritis and active disease were evaluated. A single weekly dose of 150 mg levamisole was superior to placebo in controlling disease activity. A single weekly dose of 50 mg levamisole had an intermediate effect. Adverse reactions occurred in approximately 40% of the patients with 150 mg levamisole and in approximately 20% of the patients with 50 mg levamisole or placebo. In comparison with the classical dosage schedule of levamisole (150 mg on 3 consecutive days each week) a single weekly dose of 150 mg levamisole was found to be slightly less effective but much better tolerated.
    [Abstract] [Full Text] [Related] [New Search]